Louis G. Lange's most recent trade in NewAmsterdam Pharma Company NV was a trade of 68 Ordinary Shares done . Disclosure was reported to the exchange on June 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NewAmsterdam Pharma Compan... | Louis G. Lange | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2025 | 68 | 28,186 | - | 0 | Ordinary Shares | |
| NewAmsterdam Pharma Compan... | Louis G. Lange | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2025 | 68 | 0 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Compan... | Louis Lange G. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 69 | 28,118 | - | 0 | Ordinary Shares | |
| NewAmsterdam Pharma Compan... | Louis Lange G. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 69 | 68 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Compan... | Louis G. Lange | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2025 | 69 | 137 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Compan... | Louis G. Lange | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2025 | 69 | 28,049 | - | 0 | Ordinary Shares | |
| NewAmsterdam Pharma Compan... | Louis G. Lange | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2025 | 3,308 | 3,308 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Compan... | Louis G. Lange | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 3,102 | 10,062 | - | 0 | Ordinary Shares | |
| NewAmsterdam Pharma Compan... | Louis G. Lange | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 3,102 | 206 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Compan... | Louis G. Lange | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 32,500 | 32,500 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Compan... | Louis G. Lange | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 6,960 | 6,960 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Compan... | Louis G. Lange | Director | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 13 Feb 2024 | 5,000 | 24,878 | - | 19 | 95,000 | Ordinary Shares |
| NewAmsterdam Pharma Compan... | G. Lange Louis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 10,000 | 10,000 | - | - | Option (right to buy) |